Sustainability Disclosures | Takeda Pharmaceuticals
Sustainability Disclosures
Our ESG reporting is updated regularly aligned with our transparency polices, practices, and data.
We will continuously work to improve our data capture processes and reporting of material ESG information, to demonstrate our commitment to transparency and our stakeholders.
The tables below provide links to our ESG disclosures and performance indicators under the categories of Patient, People, Planet and Values-Based Governance. Select performance indicators assured by Apex Companies, LLC are denoted with a symbol ☑. This information supplements our Annual Integrated Report.
Patient
Responsibly translate science into highly innovative, life-changing medicines and vaccines
Our approach: Responsibly translate science into highly innovative, life-changing medicines and vaccines
Our approach to Bioethics: Ethics
More on what we do: Research & Development
More on what we do: Alliances & Partnerships
- More on what we do: Areas of focus
Our Positions:
- More on what we do: Manufacturing
| Category / Metric | FY19 Data | FY20 Data | FY21 Data |
|---|---|---|---|
| Responsible innovation: R & D to address unmet medical needs | |||
| Research and development expenses (Billion JPY) | 492 | 456 | 526 |
| % of our pipeline assets that have an orphan designation | 58% | 50% | 39% |
| Total number of active R & D partnerships | 200+ | 200+ | 200+ |
Accelerate access to improve lives worldwide
Our approach: Timely, Broad and Sustainable Access
More on what we do: Our U.S. Pricing Philosophy
Our Positions:
Our approach: Access to Medicines
More on what we do: Access to Medicines 2022 Progress Report
Our Positions:
Our approach: Our Commitment to Patients
More on what we do: Access to Medicines 2022 Progress Report
More on what we do: Corporate Social Responsibility Programs in Action
Our Position: Our Position on Health Technology Assessment
| Category / Metric | FY19 Data | FY20 Data | FY21 Data | |
|---|---|---|---|---|
| Access to Medicines | ||||
| Number of patients in underserved countries and communities who have received access to Takeda’s innovative medicines and vaccines, as well as other supportive healthcare services through Takeda-sponsored and -supported clinical trials | 4,779 | 70,000 | 6,430 | ☑ |
| Number of patients who have received treatment with Takeda's innovative medicines through Takeda’s Access to Medicines Programs | 1,360 | 1,467 | 2,218 | ☑ |
| Number of countries and territories our Access to Medicines programs operate in | 54 | 54 | 58 | ☑ |
| Number of patients screened for life-threatening diseases through our Access to Medicines programs | 55,872 | 109,046 | 75,826 | ☑ |
Includes patients who access medicines through Takeda's Patient Assistance Programs (PAPs) and Compassionate Access Programs (CAPs).
Does not include patients screened in Kenya during Q4 of FY21
People
- Our approach: Talent Management
- More on what we do regarding Talent recruitment and retention efforts for scientists and research and development personnel: SASB Index Report 2022
| Category / Metric | FY21 Data | |||
|---|---|---|---|---|
| Talent Management | ||||
| Total number of new hires (absolute | % of total category ) 1 2 3 4 | 12,678 | 19% | ☑ | |
| Total number of new hires - Female | 8,316 | 22% | ☑ | |
| Total number of new hires - Male | 4,326 | 16% | ☑ | |
| Total number of new hires - Undeclared | 36 | ☑ | ||
| Total number of new hires - Age Group 1: < 30 | 6,025 | 43% | ☑ | |
| Total number of new hires - Age Group 2: 30 - 50 | 5,653 | 15% | ☑ | |
| Total number of new hires - Age Group 3: > 50 | 978 | 8% | ☑ | |
| Total number of new hires - Japan | 425 | 10% | ☑ | |
| Total number of new hires - U.S. | 8,725 | 26% | ☑ | |
| Total number of new hires - EUCAN | 1,698 | 13% | ☑ | |
| Total number of new hires - GEM | 1,830 | 21% | ☑ | |
| Percentage of open positions filled by internal candidates | 28% | |||
| Average number of years employees have been with the organization | 7.1 | |||
| Average number of years employees have been with the organization - Women | 6.1 | |||
| Average number of years employees have been with the organization - Men | 8.2 | |||
| Total global turnover rate 5 | 23% | ☑ | ||
| Total global turnover rate - Women | 28% | ☑ | ||
| Total global turnover rate - Men | 18% | ☑ | ||
| Total global turnover rate - Age Group 1: < 30 | 53% | ☑ | ||
| Total global turnover rate - Age Group 2: 30 - 50 | 18% | ☑ | ||
| Total global turnover rate - Age Group 3: > 50 | 16% | ☑ | ||
| Total global turnover rate - Japan | 5% | ☑ | ||
| Total global turnover rate - U.S. | 35% | ☑ | ||
| Total global turnover rate - EUCAN | 11% | ☑ | ||
| Total global turnover rate - GEM | 28% | ☑ | ||
| Total global turnover rate - Manager 5 | 12% | ☑ | ||
| Total global turnover rate - Individual Contributor 6 | 25% | ☑ | ||
| Total global involuntary turnover rate 7 | 6% | ☑ | ||
| Total global voluntary turnover rate 7 | 17% | ☑ |
Methodology for Human Resource Metrics changed from FY20 to FY21, therefore year on year data against the 2020 ESG Appendix may not be comparable.
Data scope limited to regular employees as of March 31, 2022
Calculated as a % of the demographic that is a new hire (0-1 year tenure) divided by the total of that demographic
There are 22 employees without DOB listed
Manager is defined as an employee with direct reports who are Takeda employees. Managers of only contractors are not included.
Individual Contributor is defined as an employee who does not have direct reports who are employees or who manages contractors only.
Data scope limited to regular employees
Our approach to Employee health, well-being and resilience: Talent Management
More on who we are: Global Environment, Health and Safety Policy
| Category / Metric | FY19 Data | FY20 Data | FY21 Data | |
|---|---|---|---|---|
| Health & Safety Incident Rates (per 200,000 hours worked) | ||||
| Total Recordable Incident Rate | 0.92 | 0.91 | 1.26 | ☑ |
| Incidents with Days Lost Rate | 0.23 | 0.25 | 0.24 | ☑ |
| Number of fatalities | 0 | 0 | 0 | ☑ |
| Fatality rate | 0 | 0 | 0 | ☑ |
| Number of high-consequence work-related injuries (excluding fatalities) | 1 | 1 | 0 | ☑ |
| Rate of high-consequence work-related injuries (excluding fatalities) | <0.01 | <0.01 | 0 | ☑ |
| Total number of hours worked | 93,100,000 | 104,900,000 | 100,800,000 |
- For Health & Safety performance indicators, the scope of Takeda operations includes all manufacturing and R&D sites, United States and Austria plasma collection centers and, commercial office locations covering approximately 95% of all employees.
- Our approach to Diversity, Equity & Inclusion: Talent Management
| Category / Metric | ||||
|---|---|---|---|---|
| Male | Female | |||
| % Workforce - Manager 1 | 59% | 41% | ☑ | |
| % Workforce - Individual Contributor 2 | 46% | 54% | ||
| Total Employees 3 | 48% | 52% | ☑ | |
| Age Group 1: <30 | Age Group 2: 30 - 50 | Age Group 3: >50 | ||
| % Workforce - Manager 1 | 2% | 71% | 27% | |
| % Workforce - Individual Contributor 2 | 22% | 60% | 18% | |
| Total Employees 3 | 19% | 62% | 19% | ☑ |
| Category / Metric | ||
|---|---|---|
| % women in all junior management positions 4 | 41% | ☑ |
| % women in all top management positions 5 | 40% | ☑ |
| % women in all management positions in revenue-generating functions 6 | 31% | ☑ |
| % women in STEM-related positions 7 | 52% | ☑ |
| Number of women on the Takeda Executive Team | 6 | ☑ |
Manager is defined as an employee with direct reports who are Takeda employees. Managers of only contractors are not included.
Individual Contributor is defined as an employee who does not have direct reports who are employees or who manages contractors only.
Includes all employees (regular, fixed term, interns, dispatched, apprentice/trainee, and temporary/limited)
Calculated as a % of women in junior management positions divided by total number of employees in those positions. Junior management positions are defined as managers at three of more levels below the CEO.
Calculated as a % of women in top management positions divided by total number of employees in those positions. Top management positions are defined as managers at two or less levels below the CEO, inclusive of the Executive team.
Calculated as a % of women in revenue generating functions positions divided by total number of employees in those positions. Revenue generating positions are defined as those related to sales.
Calculated as a % of women in Science, Technology, Engineering, and Mathematics (STEM) related positions divided by total number of employees in those positions.
- Our approach to Lifelong learning: Talent Management
| Category / Metric | FY21 Data |
|---|---|
| Engagement & Lifelong Learning | |
| Employee engagement/satisfaction rate | 79 |
| Percentage of employees receiving training per year | 100% |
| Average number of hours per FTE spent on employee development training to enhance knowledge or individual skill | 28 |
Employee engagement rate uses the Engagement Index from Takeda’s global Employee Experience Survey from 2021. Data excludes results from personnel who terminated during the survey period.
All employees complete defined global mandatory training.
At the global level, in FY21, employees were provided the opportunity to participate in several global learning experiences - Well-Being and Resilience, Hybrid Working, Data and Digital Awareness, in addition to foundational courses in Performance Management and Takeda's culture. At a business function or business unit level, learning programs in leadership development and functional skills are also provided and are dependent on the needs of the role.
Planet
| Category / Metric1 | FY19 Data | FY20 Data2 | FY21 Data | |
|---|---|---|---|---|
| Air Emissions (Metric Tons) | ||||
| Sulphur Oxides (SOx) and Nitrous Oxides (NOx) Emissions3 | 110 | 118 | 115 | ☑ |
| Waste (Metric Tons)4 | ||||
| Total Waste Generated | 73,200 | 87,000 | 87,300 | ☑ |
| Total Regulated Waste Generated | 33,000 | 43,200 | 41,300 | ☑ |
| Total Non-Hazardous Waste Generated | 40,200 | 43,800 | 46,000 | ☑ |
| Percent Waste Recycled5 | 33% | 34% | 37% | ☑ |
| Percent Waste Sent to Landfill | 21% | 21% | 21% | ☑ |
| Percent Waste Diverted from Landfill (Recycled, Incinerated, Other) | 79% | 79% | 79% | ☑ |
| Significant Spills and Releases | ||||
| Number of Notices of Violation or Citations Received | 7 | 6 | 2 | ☑ |
| Total Number and Volume of Significant Spills | 0 | 0 | 0 | ☑ |
| Product stewardship (tons)6 | ||||
| Total amount of product accepted for take-back, reuse, or disposal (Calendar Year) | N/A | 239 | 245 | ☑ |
1. Takeda has elected to use operational control as a reporting boundary guideline for its environmental data and includes:
- For total energy used and scope 1 and scope 2 GHG emissions, the scope of Takeda operations includes all manufacturing and research & development sites, United States and European plasma collection centers, Takeda headquarters, and commercial office locations.
- For all other environmental performance indicators, the scope of Takeda operations includes all manufacturing and research & development sites, United States and European plasma collection centers, and larger commercial offices where such data was available. Contributions from smaller commercial office locations are not included.
2. Previously disclosed environmental data revised to reflect acquisitions and divestitures as well as to incorporate any material corrections necessary due to external data verification activities or updated emissions factors
3. NOx and SOx emissions calculated based on fuel consumption data and emission factors from the U.S. EPA Publication "Compilation of Air Pollutant Emission Factors, AP-42, Fifth Edition, Volume 1: Stationary Point and Area Sources.“
4. Excludes Construction, Demolition and Remediation waste
5. Recycled includes materials sent off-site for processing prior to reuse
6. Data are for the total collection and disposal of unwanted household pharmaceutical products and sharps by more than 250 companies in the pharmaceutical industry, including Takeda.
Our Position: Our position on Climate Change
More on who we are: Global Environment, Health and Safety Policy
Our stories: Decarbonizing
More on what we do:
| Category / Metric1 | FY19 Data | FY20 Data2 | FY21 Data | |
|---|---|---|---|---|
| Energy (Terajoules) | ||||
| Total Energy Consumption | 7,845 | 8,000 | 8,280 | ☑ |
| Purchased Electricity (Non-Renewable) | 2,204 | 2,100 | 1,780 | ☑ |
| Purchased Electricity (Renewable)3 | 760 | 836 | 1,300 | ☑ |
| Onsite Generated Renewable Electricity | 4 | 4 | 5 | ☑ |
| Percent Electricity Sources as Renewable4 | 26% | 30% | 42% | ☑ |
| Percent Electricity as Renewable including Renewable Energy Certificates (RECs)5 | 100% | 100% | In progress | |
| Supplied Heating and Cooling | 109 | 100 | 102 | ☑ |
| Fuel Consumption6 | 4,770 | 4,960 | 5,100 | ☑ |
| Greenhouse Gas Emissions (Thousand MTCO2e)7 | ||||
| Total GHG Emissions8 | 4,502 | 4,909 | 5,210 | |
| Scope 1 Emissions | 314 | 293 | 316 | ☑ |
| CO2 | 301 | 289 | 302 | |
| CH4 | 0 | 0 | 0 | |
| N2O | 0 | 0 | 0 | |
| Refrigerants (HFCs, CFCs, HCFCs) | 13 | 15 | 14 | |
| Scope 2 Emissions - location-based methodology | 326 | 271 | 283 | ☑ |
| Scope 2 Emissions - market-based methodology | 235 | 217 | 178 | ☑ |
| Scope 3, all applicable categories | 3,953 | 4,380 | 4,716 | |
| Category 1 | 3,284 | 3,710 | 4,070 | ☑ |
| Category 2 | 65 | 50 | 35 | ☑ |
| Category 4 | 262 | 458 | 341 | ☑ |
| Category 7 | 128 | 43 | 77 | ☑ |
| Category 10 | 8 | 6 | 14 | ☑ |
| All other applicable categories | 205 | 115 | 179 | ☑ |
| % reduction in Scope 1 GHG emissions from FY2016 | 4% | 5% | 3% | |
| % reduction in Scope 2 GHG emissions from FY2016 (market-based) | 35% | 39% | 49% | |
| Carbon Neutrality5 | ||||
| Purchased Verified Emissions Reductions (VERs) - Thousand MTCO2e9 | 4308 | 4657 | In progress | ☑ |
| Purchased RECs – Terajoules | 2324 | 2185 | In progress | ☑ |
| Percentage Reported GHG Emissions Mitigated by Purchased VERs and RECs | 100% | 100% | In progress | ☑ |
1. Takeda has elected to use operational control as a reporting boundary guideline for its environmental data and includes:
For total energy used and scope 1 and scope 2 GHG emissions, the scope of Takeda operations includes all manufacturing and research & development sites, United States and European plasma collection centers, Takeda headquarters, and commercial office locations.
For all other environmental performance indicators, the scope of Takeda operations includes all manufacturing and research & development sites, United States and European plasma collection centers, and larger commercial offices where such data was available. Contributions from smaller commercial office locations are not included.
2. Previously disclosed environmental data revised to reflect acquisitions and divestitures as well as to incorporate any material corrections necessary due to external data verification activities or updated emissions factors
3. Includes renewable electricity purchased through bundled guarantees of origin contracts; excludes unbundled renewable energy purchased through renewable energy certificates.
4. Excludes electricity produced on-site through combined heat and power or fuel cell systems as well as purchased renewable energy certificates.
5. Takeda is committed to mitigating all scope 1, 2 and 3 GHG emissions through the procurement of renewable energy certificates (RECs) and verified emission reductions (VERs). Verification for carbon neutrality covers FY20 data. Procurement of necessary RECs and VERS for FY21 is in progress and will be independently verified when complete.
6. Excludes the energy content of fuel used for commercial fleet vehicles. GHG emissions from commercial fleet vehicles are included in scope 1 emissions. Calculated using the default heat content of the consumed fuels from the "GHG Emission Factors Hub" (U.S. EPA, April 22).
7. Scope 1 emissions are calculated using the GHG emission factors from the "GHG Emission Factors Hub" (U.S. EPA, April 22). Scope 2 location-based emissions from purchased electricity are calculated using the country-specific emission factors published by the IEA and U.S. EPA. Scope 2 market-based emissions from purchased electricity are calculated using the supplier-specific emission factors when available, and country-specific emission factors published by the IEA, AIB, and U.S. EPA when not available. Scope 3 emissions are calculated using activity-based emissions where available with the balance estimated using spend-based methodologies.
8. Total GHG emissions calculated using the scope 2 market-based total.
9. Purchased Verified Emission Reductions sufficient to cover FY20 scope 1 and scope 3 GHG emissions in addition to scope 2 GHG emissions from supplied heating and cooling.
Our approach: Our Commitment to the Planet
Our Approach to Key Sustainability Topics: Water Stewardship, Plastics, Biodiversity, Pharmaceuticals in the Environment and Eco-Design
More on who we are: Global Environment, Health and Safety Policy
Our stories:
| Category / Metric1 | FY19 Data | FY20 Data2 | FY21 Data | |
|---|---|---|---|---|
| Water (Thousand Cubic Meters)3,4 | ||||
| Water Withdrawal | 11,200 | 10,770 | 11,300 | ☑ |
| Water Withdrawal in Areas with High-Extremely High Water Risk | 1,223 | 1,180 | 1,090 | ☑ |
| Water Withdrawal in Areas with High-Extremely High Water Risk (% of total water withdrawl) | 11% | 11% | 10% | |
| Water Withdrawal in Areas with Low-Medium Water Risk | 9,606 | 9,590 | 10,200 | ☑ |
| Water Withdrawal in Areas with Low-Medium Water Risk (% of total water withdrawl) | 86% | 89% | 90% | |
| Water Consumed | 2,939 | 2,280 | 2,710 | ☑ |
| Water Consumed in Areas with High-Extremely High Water Risk | N/A | 174 | 165 | ☑ |
| Water Consumed in Areas with High-Extremely High Water Risk (% of total water consumed) | N/A | 8% | 6% | |
| Water Consumed in Areas with Low-Medium Water Risk | N/A | 2,100 | 2,540 | ☑ |
| Water Consumed in Areas with Low-Medium Water Risk (% of total water consumed) | N/A | 92% | 94% | |
| % of manufacturing sites located in areas considered to have “high” or “extremely high” water risk | N/A | 20% | 20% | ☑ |
| Wastewater Discharged | 8,175 | 8,490 | 8,580 | ☑ |
| % water reduction from FY2019 | N/A | 2% | -1% | |
| Biodiversity | ||||
| Number of sites owned, leased or managed in or adjacent to protected areas and/or key biodiversity areas | N/A | N/A | 29 | ☑ |
| Area of sites owned, leased or managed in or adjacent to protected areas and/or key biodiversity areas (hectares) | N/A | N/A | 329 | ☑ |
1. Takeda has elected to use operational control as a reporting boundary guideline for its environmental data and includes:
For total energy used and scope 1 and scope 2 GHG emissions, the scope of Takeda operations includes all manufacturing and research & development sites, United States and European plasma collection centers, Takeda headquarters, and commercial office locations.
For all other environmental performance indicators, the scope of Takeda operations includes all manufacturing and research & development sites, United States and European plasma collection centers, and larger commercial offices where such data was available. Contributions from smaller commercial office locations are not included.
2. Previously disclosed environmental data revised to reflect acquisitions and divestitures as well as to incorporate any material corrections necessary due to external data verification activities or updated emissions factors
3. Overall water risk rating based on the World Resource Institute Aqueduct 3.0 tool. Overall water risk measures all water-related risks, by aggregating all selected indicators from the Physical Risk Quantity, Physical Risk Quality, and Regulatory, and Reputational Risk categories. Higher values indicate higher water risk.
4. Water consumed represents the difference between water withdrawals and wastewater discharges.
| Category / Metric1 | FY19 Data | FY20 Data2 | FY21 Data | |
|---|---|---|---|---|
| Environmental Management Systems | ||||
| Number of EHS audits performed3 | 24 | 20 | 24 | |
| % of manufacturing sites certified to ISO 14001 | 63% | 73% | 73% | ☑ |
| % of manufacturing sites certified to ISO 50001 | 3% | 3% | 3% | ☑ |
| % of manufacturing sites certified to ISO 45001 | 38% | 53% | 50% | ☑ |
1.Takeda has elected to use operational control as a reporting boundary guideline for its environmental data and includes:
For total energy used and scope 1 and scope 2 GHG emissions, the scope of Takeda operations includes all manufacturing and research & development sites, United States and European plasma collection centers, Takeda headquarters, and commercial office locations.
For all other environmental performance indicators, the scope of Takeda operations includes all manufacturing and research & development sites, United States and European plasma collection centers, and larger commercial offices where such data was available. Contributions from smaller commercial office locations are not included.
2. Previously disclosed environmental data revised to reflect acquisitions and divestitures as well as to incorporate any material corrections necessary due to external data verification activities or updated emissions factors
3. EHS audits performed includes internal and external third-party audits managed by the corporate EHS function.
A list of our ISO 14000-45001 Certified Sites can be found here.
Values-based governance
- Our approach: Corporate Governance
More on who we are:
Information on Annual Shareholders Meetings, including Notices of Resolutions and Results of the Exercise of Voting Rights: Annual Shareholders Meetings
Information on total rewards and compensation, see Takeda’s Executive Compensation Overview and Corporate Governance Report
- Our Positions: Our Position on Taxation
Our approach to Quality management: Ethics
Our Positions: Our Position on Counterfeit, Falsified and Illegal Trading of Healthcare Products
Takeda products with safety alerts can be found in the FDA MedWatch Safety Alerts for Human Medical Products database
Historical product recalls can be found in the FDA Drug Recalls database
Our approach: Supply Chain
More on who we are: Takeda Supplier Code of Conduct
More on what we do: Suppliers
Reporting on Third Party Labor Rights:
- Our approach: Ethics (including Medical Ethics, Bioethics and Human Rights)
More on who we are:
- More about what we do on Safety of Clinical Trial Participants: SASB Index Report 2022
Our approach: Risk & Crisis Management
Matters related to internal controls and risk management rules: Corporate Governance Report
- Our approach: Corporate Giving
More about what we do:
| Category / Metric | FY21 Data | |
|---|---|---|
| Ethics and Compliance | ||
| Total percentage of employees trained on Takeda’s anti-corruption policies and procedures | 100% | ☑ |
| Total percentage of employees trained on Takeda’s anti-corruption policies and procedures - Japan | 100% | ☑ |
| Total percentage of employees trained on Takeda’s anti-corruption policies and procedures - U.S. | 100% | ☑ |
| Total percentage of employees trained on Takeda’s anti-corruption policies and procedures - EUCAN | 100% | ☑ |
| Total percentage of employees trained on Takeda’s anti-corruption policies and procedures - GEM | 100% | ☑ |
| Total percentage of employees trained on Takeda’s Code of Conduct | 97% | |
| Total percentage of employees trained on Takeda’s Code of Conduct - Japan | 98% | |
| Total percentage of employees trained on Takeda’s Code of Conduct - U.S. | 96% | |
| Total percentage of employees trained on Takeda’s Code of Conduct - EUCAN | 97% | |
| Total percentage of employees trained on Takeda’s Code of Conduct - GEM | 98% | |
| Total number of incidents of corruption confirmed during the year, but related to previous years | 1 | ☑ |
| Total number of incidents of corruption confirmed during the year, related to year | 1 | ☑ |
| Total number of discrimination and harassment incidents during the year | 28 | |
| Total losses as a result of legal proceedings associated with discrimination and harassment incidents (JPY Million) | 235.5 | ☑ |
| Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments to delay bringing an authorized generic product to market1 | 0 | ☑ |
| Total losses as a result of legal proceedings associated with clinical trials in developing countries (JPY Million) | 0 | ☑ |
| Total losses as a result of legal proceedings associated with false marketing claims (JPY Million) | 0 | ☑ |
| Total losses as a result of legal proceedings associated with corruption and bribery (JPY Million) | 0 | ☑ |
| Total losses as a result of legal proceedings associated with fraud, insider trading, anti-trust, anti-competition, market manipulation, malpractice or violations of other related regulations (JPY Million) | 203.3 | ☑ |
| Economic Disclosures | ||
| Vitality Index - Percentage of gross revenue from products commercialized in the last five years2 | 4.2% | |
| Quality Management | ||
| Number of Class I recalls3 | 0 | ☑ |
| Number of Class II recalls3 | 0 | ☑ |
| Supply Chain | ||
| Number of total active suppliers globally | 62,285 | |
| Supplier diversity spend - all diverse categories, including small and large business (USD Million)4 | 708.7 | |
| Number of PSCI sustainability audits conducted6 | 5 | |
| Global CSR | ||
| Amount invested in long-term philanthropic commitments FY16-FY21 (JPY Billion) | 16.2 | |
| Public Policy Engagement | ||
| Total spend on lobbying, interest representation or similar in the United States of America, the countries of the European Union, and Japan5 (Million JPY) | 659.8 |
1.Takeda has not entered into any settlement with an ANDA filer that provided any so-called “payment for delay,” including any agreement by Takeda not to launch an authorized generic version of Takeda’s branded product for a defined time period after the ANDA-filer’s launch.
2. Takeda’s vitality index, defined as the revenue contribution from products commercialized in the last five years, is 4.2% for our FY ending March 2022 (vs 3.5% for the prior year). This includes key contributions from our rare disease and oncology portfolios, such as from Takhzyro for hereditary angioedema and Alunbrig for non-small cell lung cancer. For more information on this metric, please see our WEF Index Table, under "Vitality Index".
3. The scope of this data is U.S. only and includes both enforced and voluntary recalls.
4. Takeda's FY21 target for supplier diversity spend (including small and large businesses) was USD $594 million, which was achieved and surpassed.
5. The United States of America, the countries of the European Union, and Japan accounted for 87.2% of our revenues in 2021. Conversion of currency and % of revenues has been calculated as per Takeda’s FY2021 Q4 Earnings Announcement (1 USD = 112 JPY, 1 EUR = 131 JPY).
6. Takeda's FY21 target for number of PSCI sustainability audits conducted was 5, which was achieved.